Expression of EpCAMMF and EpCAMMT variants in human carcinomas

Journal of Clinical Pathology

Volumn 67, Issue 5, 2014, Pages 408-414

  Fong, Dominic ^a,b,c,d   Seeber, Andreas ^a,b,c   Terracciano, Luigi ^e   Kasal, Armin ^f   Mazzoleni, Guido ^f   Lehne, Florian ^a,b,c   Gastl, Guenther ^c   Spizzo, Gilbert ^a,b,c,d  

^a TYROLEAN CANCER RESEARCH INSTITUTE   (Austria)

^b Center for Personalized Cancer Medicine GmbH   (Austria)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^d FRANZ TAPPEINER HOSPITAL   (Italy)

^e UNIVERSITY OF BASEL   (Switzerland)

^f CENTRAL HOSPITAL OF BOLZANO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER; CELL ADHESION MOLECULES; IMMUNOHISTOCHEMISTRY;

ANTIGENS, NEOPLASM; CARCINOMA; CELL ADHESION MOLECULES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTEIN ISOFORMS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84898823986     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2013-201932     Document Type: Article

References (34)

1. Balzar M, Winter MJ, de Boer CJ, et al. The biology of the 17-1A antigen (Ep-CAM). J Mol Med (Berl) 1999;77:699-712.
2. Litvinov SV, Balzar M, Winter MJ, et al. Epithelial cell adhesion molecule (Ep-CAM) modulates cell-cell interactions mediated by classic cadherins. J Cell Biol 1997;139:1337-48.
3. Maetzel D, Denzel S, Mack B, et al. Nuclear signalling by tumour-associated antigen EpCAM. Nat Cell Biol 2009;11:162-71.
4. Dontu G, Al-Hajj M, Abdallah WM, et al. Stem cells in normal breast development and breast cancer. Cell Prolif 2003;36:59-72.
5. O'Brien CA, Pollett A, Gallinger S, et al. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007;445:106-10.
6. Seimetz D, Lindhofer H, Bokemeyer C. Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy. Cancer Treat Rev 2010;36:458-67.
7. Niedzwiecki D, Bertagnolli MM, Warren RS, et al. Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: results from CALGB 9581. J Clin Oncol 2011;29:3146-52.
8. Carpenter G, Red Brewer M. EpCAM: another surface-to-nucleus missile. Cancer Cell 2009;15:165-6.
9. Ralhan R, He HC, So AK, et al. Nuclear and cytoplasmic accumulation of Ep-ICD is frequently detected in human epithelial cancers. PLoS One 2010;5:e14130.
10. Schnell U, Kuipers J, Giepmans BN. EpCAM proteolysis: new fragments with distinct functions? Biosci Rep 2013;33:e00030.
11. Went PT, Lugli A, Meier S, et al. Frequent EpCam protein expression in human carcinomas. Hum Pathol 2004;35:122-8.
12. Fong D, Moser P, Kasal A, et al. Loss of membranous expression of the intracellular domain of EpCAM is a frequent event and predicts poor survival in patients with pancreatic cancer. Histolopathology 9 Oct 2013. Epub ahead of print. doi:10.1111/his.12307
13. Pai RK, West RB. MOC-31 exhibits superior reactivity compared with Ber-EP4 in invasive lobular and ductal carcinoma of the breast: a tissue microarray study. Appl Immunohistochem Mol Morphol 2009;17:202-6.
14. Gastl G, Spizzo G, Obrist P, et al. Ep-CAM overexpression in breast cancer as a predictor of survival. Lancet 2000;356:1981-2.
15. Spizzo G, Fong D, Wurm M, et al. EpCAM expression in primary tumour tissues and metastases: an immunohistochemical analysis. J Clin Pathol 2011;64:415-20.
16. Zhang D, Salto-Tellez M, Putti TC, et al. Reliability of tissue microarrays in detecting protein expression and gene amplification in breast cancer. Mod Pathol 2003;16:79-84.
17. Alberti S, Ambrogi F, Boracchi P, et al. Cytoplasmic Trop-1/Ep-CAM overexpression is associated with a favorable outcome in node-positive breast cancer. Jpn J Clin Oncol 2012;42:1128-37.
18. Lin CW, Liao MY, Lin WW, et al. Epithelial cell adhesion molecule regulates tumor initiation and tumorigenesis via activating reprogramming factors and epithelial-mesenchymal transition gene expression in colon cancer. J Biol Chem 2012;287:39449-59.
19. Kunavisarut T, Kak I, Macmillan C, et al. Immunohistochemical analysis based Ep-ICD subcellular localization index (ESLI) is a novel marker for metastatic papillary thyroid microcarcinoma. BMC Cancer 2012;12:523.
20. Ralhan R, Cao J, Lim T, et al. EpCAM nuclear localization identifies aggressive thyroid cancer and is a marker for poor prognosis. BMC Cancer 2010;10:331.
21. Varga M, Obrist P, Schneeberger S, et al. Overexpression of epithelial cell adhesion molecule antigen in gallbladder carcinoma is an independent marker for poor survival. Clin Cancer Res 2004;10:3131-6.
22. Spizzo G, Went P, Dirnhofer S, et al. Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer. Gynecol Oncol 2006;103:483-8.
23. Benko G, Spajic B, Kruslin B, et al. Impact of the EpCAM expression on biochemical recurrence-free survival in clinically localized prostate cancer. Urol Oncol 2013;31:468-74.
24. Stoecklein NH, Siegmund A, Scheunemann P, et al. Ep-CAM expression in squamous cell carcinoma of the esophagus: a potential therapeutic target and prognostic marker. BMC Cancer 2006;6:165.
25. Fong D, Steurer M, Obrist P, et al. Ep-CAM expression in pancreatic and ampullary carcinomas: frequency and prognostic relevance. J Clin Pathol 2008;61:31-5.
26. Seligson DB, Pantuck AJ, Liu X, et al. Epithelial cell adhesion molecule (KSA) expression: pathobiology and its role as an independent predictor of survival in renal cell carcinoma. Clin Cancer Res 2004;10:2659-69.
27. Songun I, Litvinov SV, van de Velde CJ, et al. Loss of Ep-CAM (CO17-1A) expression predicts survival in patients with gastric cancer. Br J Cancer 2005;92:1767-72.
28. Martowicz A, Spizzo G, Gastl G, et al. Phenotype-dependent effects of EpCAM expression on growth and invasion of human breast cancer cell lines. BMC Cancer 2012;12:501.
29. Gostner JM, Fong D, Wrulich OA, et al. Effects of EpCAM overexpression on human breast cancer cell lines. BMC Cancer 2011;11:45.
30. Soysal SD, Muenst S, Barbie T, et al. EpCAM expression varies significantly and is differentially associated with prognosis in the luminal B HER2, basal-like, and HER2 intrinsic subtypes of breast cancer. Br J Cancer 2013;108:1480-7.
31. Eichelberg C, Chun FK, Bedke J, et al. Epithelial cell adhesion molecule is an independent prognostic marker in clear cell renal carcinoma. Int J Cancer 2013;132:2948-55.
32. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988;319:525-32.
33. Aytes A, Mollevi DG, Martinez-Iniesta M, et al. Stromal interaction molecule 2 (STIM2) is frequently overexpressed in colorectal tumors and confers a tumor cell growth suppressor phenotype. Mol Carcinog 2012;51:746-53.
34. Gosens MJ, van Kempen LC, van de Velde CJ, et al. Loss of membranous Ep-CAM in budding colorectal carcinoma cells. Mod Pathol 2007;20:221-32.